computer-aided-design

(4)
Company
Revalize Bought the Software Under the Factory Floor. Now It Has to Make the Pieces Fit
Saas · Enterprise

Revalize Bought the Software Under the Factory Floor. Now It Has to Make the Pieces Fit

Revalize stitched together 19 specialist brands to give manufacturers one route from sketch to quote. The opportunity is large; so is the integration job.

manufacturing-software · configure-price-quoteRead →
Company
PTC
Enterprise · Saas · Ai

PTC

For four decades, PTC has sold the software behind the objects people rarely think of as software projects. Now it is simplifying its portfolio around a bigger bet: that clean, connected product data will become the operating memory for industrial AI.

industrial-software · product-lifecycle-managementRead →
Company
TeselaGen Biotechnology
Ai · Saas · Health

TeselaGen Biotechnology

TeselaGen Biotechnology builds an AI-powered, cloud-based operating system for biological R&D. Spun out of the Department of Energy's Joint BioEnergy Institute and founded by Stanford and Berkeley scientists, its platform - organized around the Design-Build-Test-Learn cycle with DESIGN, BUILD, TEST and DISCOVER modules - lets researchers design DNA libraries, generate lab-robot assembly protocols, capture experimental data and apply machine learning to converge on better biological products faster. Customers span industrial biotech, biopharma and academia, including Amgen, LanzaTech, Twist Bioscience, Arzeda and Stanford.

synthetic-biology · dna-assemblyRead →
Company
Asimov
Ai · Health · Developer Tools

Asimov

Asimov is a Boston-based synthetic biology company building computer-aided design (CAD) tools for engineering living cells. Founded in 2017 by bioengineers from MIT and Boston University, it combines mammalian synthetic biology, software, and machine learning through its Kernel platform and 'Edge' production systems to help drug makers design and manufacture cell, gene, and RNA therapies more reliably. The company has raised over $200M, including a $175M Series B in January 2023 led by CPP Investments.

synthetic-biology · biotechnologyRead →